Science Explorer Back to mapMap
Institution · Krankenhaus Nordwest

Most cited papers from Krankenhaus Nordwest

What are the most cited papers from Krankenhaus Nordwest?

The most cited paper from Krankenhaus Nordwest is "Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial" (Salah‐Eddin Al‐Batran et al., 2019), with 2,700 citations. Next come "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial" (1,759) and "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial" (1,515).

Showing 50 of 60 papers. Every paper with more than 224 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Salah‐Eddin Al‐Batran et al. · The Lancet 11 Apr 2019 2,700
2 FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Volker Heinemann et al. · The Lancet Oncology 31 Jul 2014 1,759
3 Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet 19 Feb 2013 1,515
4 Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial Scott Joseph Antonia et al. · The Lancet Oncology Open access 5 Jun 2016 1,263
5 Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Dung Thi Le et al. · Journal of Clinical Oncology Open access 14 Nov 2019 1,038
6 One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor Heikki Joensuu et al. · JAMA 27 Mar 2012 982
7 Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer Matthew David Hellmann, Margaret K. Callahan, Mark Magdi Awad et al. · Cancer Cell Open access May 2018 913
8 International consensus statement on the peri‐operative management of anaemia and iron deficiency Manuel Múñoz, Austin George Acheson, Michael Auerbach et al. · Anaesthesia Open access 20 Dec 2016 876
9 Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie Salah‐Eddin Al‐Batran, Joerg Thomas Hartmann, Stephan Probst et al. · Journal of Clinical Oncology 18 Mar 2008 788
10 Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1 Marie Marchand et al. · International Journal of Cancer 18 Jan 1999 788
11 Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Salah‐Eddin Al‐Batran et al. · The Lancet Oncology 22 Oct 2016 751
12 Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes Elke Jäger, Yao-Tseng Chen, Jan Wouter Drijfhout et al. · The Journal of Experimental Medicine Open access 19 Jan 1998 731
13 SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition Annika Nelde et al. · Nature Immunology Open access 30 Sep 2020 647
14 Anti-CCR4 mAb selectively depletes effector-type FoxP3 + CD4 + regulatory T cells, evoking antitumor immune responses in humans Daisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda et al. · Proceedings of the National Academy of Sciences Open access 14 Oct 2013 632
15 Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines Lawrence T. Goodnough, Alice G. Maniatis, Peter H. Earnshaw et al. · British Journal of Anaesthesia Open access 10 Dec 2010 545
16 Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology Open access 23 Jul 2018 508
17 NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial Zev A. Wainberg, Davide Melisi, Teresa Mercade Macarulla et al. · The Lancet Open access 11 Sep 2023 504
18 Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study Atsushi Ohtsu, Jaffer A. Ajani, Yu-Xian Bai et al. · Journal of Clinical Oncology Open access 17 Sep 2013 500
19 Biochemical Markers and Hematologic Indices in the Diagnosis of Functional Iron Deficiency Christian Thomas, Lothar Thomas · Clinical Chemistry Jul 2002 493
20 Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer Salah‐Eddin Al‐Batran et al. · JAMA Oncology Open access 27 Apr 2017 485
21 NY‐ESO‐1: Review of an Immunogenic Tumor Antigen Sacha Gnjatic, Hiroyoshi Nishikawa, Achim A. Jungbluth et al. · Advances in cancer research Book chapter 2006 458
22 The Leukotriene C4 Transporter MRP1 Regulates CCL19 (MIP-3β, ELC)–Dependent Mobilization of Dendritic Cells to Lymph Nodes Davide F. Robbiani, Rick A. Finch, Dirk Jäger et al. · Cell Open access Nov 2000 458
23 Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma Mathias Rummel, Salah Eddin Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology Open access 20 May 2005 442
24 Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers Elke Jäger, Sacha Gnjatic, Yasuhiro Nagata et al. · Proceedings of the National Academy of Sciences Open access 10 Oct 2000 426
25 FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial Sebastian Stintzing et al. · The Lancet Oncology 2 Sep 2016 424
26 Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 Marie-Claude Marchand et al. · International Journal of Cancer 11 Dec 1995 420
27 Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies Simon Tiberi, Nelita du Plessis, Gerhard Walzl et al. · The Lancet Infectious Diseases Open access 23 Mar 2018 410
28 Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study Kohei Shitara et al. · The Lancet Oncology Open access 19 Dec 2023 384
29 FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma Uğur Şahin, Ö. Türeci, Georgy Moiseevich Manikhas et al. · Annals of Oncology Open access 21 Feb 2021 380
30 Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 Neal Ready, Anna F. Farago, Filippo de Braud et al. · Journal of Thoracic Oncology Open access 10 Oct 2018 380
31 Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer Ralf‐Dieter Hofheinz, Salah‐Eddin Al‐Batran, Frank Hartmann et al. · Oncology Research and Treatment 2003 374
32 Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis Yelena Yuriy Janjigian, Dominique Werner, Claudia Pauligk et al. · Annals of Oncology Open access 12 Jun 2012 367
33 Validity of the Six-Minute Walk Test in Cancer Patients Katharina Schmidt, Lutz Vogt, Christian Thiel et al. · International Journal of Sports Medicine 26 Feb 2013 364
34 Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial Daniel V.T. Catenacci et al. · The Lancet Oncology Open access 25 Sep 2017 349
35 Gallbladder carcinoma: Prognostic factors and therapeutic options Thorsten Oliver Goetze · World Journal of Gastroenterology Open access 2015 343
36 A Multiplex Polymerase Chain Reaction Protocol for the Simultaneous Analysis of the GlutathioneS-Transferase GSTM1 and GSTT1 Polymorphisms Michael Arand, Roland Mühlbauer, Jan Georg Hengstler et al. · Analytical Biochemistry Apr 1996 339
37 Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort Neal Ready, Patrick Alexander Ott, Matthew David Hellmann et al. · Journal of Thoracic Oncology Open access 17 Oct 2019 330
38 Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer Georg Wolf, Robert Elez, A Doermer et al. · Oncogene 6 Feb 1997 327
39 Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer Yelena Yuriy Janjigian et al. · New England Journal of Medicine Jun 2025 311
40 Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma Elke Jäger, Mark Ringhoffer, M. Altmannsberger et al. · International Journal of Cancer 10 Apr 1997 305
41 Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo Elke J�ger, Mark Ringhoffer, Hans Peter Dienes et al. · International Journal of Cancer 3 Jul 1996 297
42 Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library Yao‐Tseng Chen, Ali Osmay Gure, Solam Tsang et al. · Proceedings of the National Academy of Sciences Open access 9 Jun 1998 295
43 Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial Charles S. Fuchs et al. · The Lancet Oncology Open access144 authors Feb 2019 288
44 Expression of MAGE genes in primary and metastatic cutaneous melanoma Francis Brasseur et al. · International Journal of Cancer 3 Nov 1995 287
45 Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED ): an open-label randomised controlled trial Rolf Wachter et al. · The Lancet Neurology Open access 8 Feb 2017 286
46 Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG Peyman Hadji et al. · Journal of bone oncology Open access 23 Mar 2017 281
47 Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Salah Eddin Al-Batran, Joerg Thomas Hartmann, Ralf‐Dieter Hofheinz et al. · Annals of Oncology Open access Aug 2008 281
48 A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity Jonas S. Heitmann et al. · Nature Open access 23 Nov 2021 279
49 Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variantsin vivo Elke Jäger, Mark Ringhoffer, Julia Karbach et al. · International Journal of Cancer Open access 16 May 1996 271
50 A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study James Andrew Thomas et al. · European Urology 14 Aug 2015 259

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.